Welcome to Helix Talk, an educational podcast for healthcare students and providers covering real-life clinical pearls, professional pharmacy topics, and drug therapy discussions.

This podcast is provided by pharmacists and faculty members at Rosal Franklin University College of Pharmacy.

This podcast contains general information for educational purposes only. This is not professional

advice and should not be used in lieu of obtaining advice from a qualified health care provider.

And now on to the show.

Welcome to Helix Talk Episode 50. I'm your co-host Dr. Kane. I'm Dr. Schumann. And I'm Dr. Patel.

And to celebrate Episode 50, we've decided that from now on, every three weeks when we introduce

our Helix Talk episodes, we're going to have some provocative titles to help introduce the

listeners to the topic a little bit better and maybe draw them in a little bit more.

Well, that's very exciting.

And I did not realize we were at episode 50, so I guess it calls for a celebration.

The title of this episode is three shocking recommendations from chest 2016 that will blow your mind.

So essentially we're talking today about the 2016 chest guidelines, which are guidelines dealing with basically anticoagulants and we picked

out three of the recommendations from the chest guidelines that either were very surprising

to us or that we just flat out don't necessarily agree with.

So first and foremost the controversy about what do we call these drugs, right? I've

heard so many acronyms. I don't even know where to start. I've

heard noax. I've heard doax. I've heard soax where tea is kind of like a little silent.

So what's the deal? When they first came out, we called them noax because they were novel or new.

That's what the N stood for. And at some point, someone said, hey, at some point these aren't going to be new or novel anymore.

What are we going to call them at that point?

So the name didn't really age well.

...